Reference
·Supporting source
Siam Bioscience vaccine output capacity (2024)
~200M doses/year
Siam Bioscience, the Crown Property Bureau-owned biopharmaceutical company that produced AstraZeneca COVID-19 vaccine under regional licence during 2021-2023, operates Thailand's largest single biologics manufacturing footprint with approximately 200 million doses per year of fill-finish capacity as of 2024 per company disclosures and PReMA tracking. Post-pandemic the line has been re-tooled for biosimilar oncology and chronic disease biologics under partnerships including Lupin and Curative. The facility is one of only a handful of WHO-prequalified biologics fill-finish sites in ASEAN.
Figure in context
Siam Bioscience, the Crown Property Bureau-owned biopharmaceutical company that produced AstraZeneca COVID-19 vaccine under regional licence during 2021-2023, operates Thailand's largest single biologics manufacturing footprint with approximately 200 million doses per year of fill-finish capacity as of 2024 per company disclosures and PReMA tracking. Post-pandemic the line has been re-tooled for biosimilar oncology and chronic disease biologics under partnerships including Lupin and Curative. The facility is one of only a handful of WHO-prequalified biologics fill-finish sites in ASEAN.
Siam Bioscience, the Crown Property Bureau-owned biopharmaceutical company that produced AstraZeneca COVID-19 vaccine under regional licence during 2021-2023, operates Thailand's largest single biologics manufacturing footprint with approximately 200 million doses per year of fill-finish capacity as of 2024 per company disclosures and PReMA tracking. Post-pandemic the line has been re-tooled for biosimilar oncology and chronic disease biologics under partnerships including Lupin and Curative. The facility is one of only a handful of WHO-prequalified biologics fill-finish sites in ASEAN.
Time scope
2024 nameplate
Source basis
Supporting source
Interpretation notes
What this tells you
Siam Bioscience, the Crown Property Bureau-owned biopharmaceutical company that produced AstraZeneca COVID-19 vaccine under regional licence during 2021-2023, operates Thailand's largest single biologics manufacturing footprint with approximately 200 million doses per year of fill-finish capacity as of 2024 per company disclosures and PReMA tracking. Post-pandemic the line has been re-tooled for biosimilar oncology and chronic disease biologics under partnerships including Lupin and Curative. The facility is one of only a handful of WHO-prequalified biologics fill-finish sites in ASEAN.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical manufacturing factory-gate revenue (2020-2024)
Thai FDA, Pharmaceutical Research and Manufacturers Association of Thailand, Krungsri Research, Bangkok Post pharma coverage
Thailand pharmaceutical generic vs branded mix (2024)
PReMA, IQVIA Thailand, Thai FDA, Government Pharmaceutical Organization
Thailand pharmaceutical manufacturer revenue share (2024)
PReMA, Thai FDA, GPO annual report, Mega Lifesciences, industry estimates
BOI Future Medicine approved projects (2020-2024)
Thailand Board of Investment, BOI Future Medicine sector briefing, NESDC
Thailand FDA GMP-certified pharmaceutical facility count (2024)
Thai FDA Drug Control Division, PIC/S accession documentation, PReMA, industry estimates
Thailand pharma facilities with EU GMP cross-certification (2024)
Thai FDA, EudraGMDP database, PReMA, operator disclosures
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.